[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617067":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":33,"responsibleParty":49,"collaborators":20,"id":51,"slug":52,"hasResults":53,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":53,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":73,"overallStatus":83,"whyStopped":20,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Cortex Neurovascular","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"TEMMA Procedure (Targeted Embolization for Migraine Management)","EXPERIMENTAL","Participants with refractory migraine undergo the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy addressing meningeal arterial contributors to migraine. Treatment is performed using FDA-cleared devices per institutional clinical practice. Procedural details and adjunctive assessments are individualized and not dictated by the study protocol. Outcomes are evaluated using within-subject comparison to baseline.",[13],"Device: TEMMA Endovascular Treatment",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","TEMMA Endovascular Treatment","Endovascular treatment targeting meningeal arterial contributors to migraine performed as part of the TEMMA procedure (Targeted Embolization for Migraine Management) using FDA-cleared devices. Procedural techniques and adjunctive assessments are individualized at the discretion of the treating physician and are not standardized within the study.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Dennis Wang, MD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","253-761-4200","dwang@cortexmgmt.com",{"name":31,"role":27,"phone":28,"phoneExt":20,"email":32},"Brian Kott, MD","bkott@tranow.com",[34],{"facility":35,"status":20,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Cortex Neurovascular \u002F TRA Union","Tacoma","Washington","98405","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-122.44429,47.25288,{"lat":45,"lon":44},[48],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"type":50,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100617067","embrace-study-enduring-migraine-benefit-from-responsive-artery-coil-embolization-100617067",false,"NCT07313800","EMBRACE Study: Enduring Migraine Benefit From Responsive Artery Coil Embolization","Enduring Migraine Benefit From Responsive Artery Coil Embolization (EMBRACE): A Single-Site, Non-Significant Risk Pilot Study of Middle Meningeal Artery Embolization Using FDA-Cleared Coils for Refractory Episodic Migraine","EMBRACE","Inclusion Criteria:\n\n* Age 18-60 years\n* Diagnosis of migraine (with or without aura)\n\n  -≥8 headache days per month\n* Failure of ≥2 preventive medication classes\n* Ability to complete electronic headache diary and surveys\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Secondary headache disorders\n* Prior MMA embolization\n* Contraindication to angiography or embolization\n* Pregnancy\n* Inability to comply with follow-up","ALL","18 Years","60 Years",{"count":63,"type":64},25,"ESTIMATED","INTERVENTIONAL",[67],"NA","This single-site, open-label pilot study evaluates the safety, feasibility, and potential durability of the TEMMA procedure (Targeted Embolization for Migraine Management), an endovascular treatment strategy targeting meningeal arterial contributors to migraine. Adults aged 18-60 with refractory migraine despite prior preventive therapies are eligible. The study assesses migraine outcomes over 12 months using patient-reported headache frequency, pain intensity, acute medication use, migraine-related disability (MIDAS), and quality-of-life measures (MSQ v2.1).",[70,71,72],"Migraine Disorders","Refractory Migraine","Chronic Migraine",[74,75,71,76,77,78,79,80,81,82],"Middle Meningeal Artery Embolization","MMA Embolization","Coil Embolization","Neurovascular Intervention","Migraine Prevention","TEMMA","TEMMA procedure","TEMMA protocol","Targeted Embolization for Migraine Management","NOT_YET_RECRUITING","2026-02-02",{"date":86,"type":87},"2026-02-04","ACTUAL",{"date":89,"type":64},"2026-03-01",{"date":91,"type":64},"2028-03-01",{"name":5,"class":6},1]